United States Patent 9,468,639: Flibanserin Method-of-Use Claims, Patent Scope, and Generic Risk

U.S. Patent No. 9,468,639 covers the use of flibanserin, or an acid-addition salt, to treat decreased, absent, or inhibited sexual desire. The claims cover both female and male patients and include broad daily-dose and dosage-unit ranges. The patent is a method-of-use patent, not a compound, formulation, manufacturing, or composition-of-matter patent.

Its commercial significance is limited by three factors: the claims largely track the therapeutic use approved for Addyi; several dose ranges are substantially broader than the marketed 100 mg regimen; and later generic entry has reduced the practical exclusionary value of the patent estate. Because flibanserin is a small molecule, biosimilar law does not apply.

What does U.S. Patent 9,468,639 protect?

The patent protects administering flibanserin to treat sexual-desire disorders. Independent claims 1, 8, and 14 define three overlapping therapeutic concepts:

Independent claim	Claimed condition	Active ingredient	Patient limitation	Dose limitation
Claim 1	Decreased sexual desire	Flibanserin or pharmaceutically acceptable acid-addition salt	None	None
Claim 8	Absent sexual desire	Flibanserin or pharmaceutically acceptable acid-addition salt	None	None
Claim 14	Inhibited sexual desire	Flibanserin or pharmaceutically acceptable acid-addition salt	None	None

The dependent claims add sex-specific and dosage limitations. Claims 2, 9, and 15 narrow the patient to females. Claims 3, 10, and 16 narrow the patient to males.

The claims do not require:

A particular formulation;
Oral administration;
A particular treatment duration;
A particular disease etiology;
A diagnosis of female sexual interest/arousal disorder;
Concomitant counseling or psychotherapy;
A particular flibanserin polymorph;
A particular salt;
A particular pharmacokinetic profile.

The absence of those limitations makes the independent claims potentially broad, but it also exposes them to prior-art, written-description, enablement, indefiniteness, and claim-construction challenges.

What chemical forms of flibanserin are covered?

The claims cover flibanserin and a “pharmaceutically acceptable acid addition salt thereof.” The language extends beyond the free-base active ingredient to qualifying acid-addition salts.

A product containing flibanserin hydrochloride or another pharmaceutically acceptable acid-addition salt could fall within the chemical limitation if the other claim requirements are met. The claims do not expressly require a specific crystal form, particle size, excipient system, release profile, or manufacturing process.

How do the dosage claims affect patent scope?

The patent contains unusually broad and overlapping dose ranges.

Claims	Claimed dosing range
Claim 4	About 0.1 mg to 400 mg per day
Claim 5	About 1 mg to 300 mg per day
Claim 6	Dosage unit containing about 0.01 mg to 100 mg
Claim 7	Dosage unit containing about 0.1 mg to 50 mg
Claim 11	About 2 mg to 200 mg per day
Claim 12	About 0.1 mg to 100 mg per day
Claim 13	Dosage unit containing about 150 mg
Claim 17	About 0.1 mg to 400 mg per day
Claim 18	Dosage unit containing about 100 mg
Claim 19	Dosage unit containing about 80 mg
Claim 20	Dosage unit containing about 50 mg

The marketed Addyi regimen is 100 mg orally once daily at bedtime, according to the FDA-approved labeling.[2] That regimen falls squarely within the scope of claims 4, 5, 11, 12, and 17, and corresponds directly to claim 18’s 100 mg dosage-unit limitation.

The dose claims create overlapping fallback positions. If a broad treatment claim were invalidated or construed narrowly, a patent holder could rely on a narrower dose claim. The overlap also reduces the practical value of designing around the patent through routine dose changes, because numerous claims cover materially different dosage windows.

Does Patent 9,468,639 cover Addyi’s approved use?

Yes, materially. Addyi is flibanserin, approved by the FDA for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.[1][2] The patent’s claims use broader terminology, including “decreased,” “absent,” and “inhibited” sexual desire.

The patent does not use the full FDA diagnostic formulation as a limitation. It does not require that the condition be:

Acquired rather than lifelong;
Generalized rather than situational;
Present in a premenopausal woman;
Associated with personal distress;
Unrelated to medication, a medical condition, or relationship factors.

This creates a distinction between regulatory labeling and patent scope. The FDA label limits approved use. The patent claims, on their face, reach a broader patient population and include male patients.

What is the significance of the male-patient claims?

Claims 3, 10, and 16 expressly cover treatment of male patients. Addyi’s FDA approval is limited to premenopausal women, so the male-patient claims do not correspond to the approved indication.

Those claims may have limited standalone commercial value because the FDA-approved product label does not authorize the male indication. They could still matter in litigation involving off-label use, clinical research, or a later regulatory strategy. Their breadth also creates potential written-description and enablement issues if the specification does not adequately support efficacy across male patients.

Is Patent 9,468,639 a formulation patent?

No. Patent 9,468,639 is principally a therapeutic method-of-use patent.

It does not require:

A specific tablet composition;
A particular excipient;
Immediate-release or extended-release delivery;
A coating;
A dissolution profile;
A particle-size distribution;
A specific salt form beyond the broad acid-addition-salt language;
A particular manufacturing method.

A generic tablet could infringe the method claims through the labeled indication and dosing instructions even if its formulation, excipients, manufacturing process, and physical characteristics differ from Addyi’s. The analysis would depend on the product label, induced-infringement theory, prescriber behavior, and the enforceability of the relevant claims.

Separate formulation, salt, polymorph, or manufacturing patents would need to be analyzed independently. Patent 9,468,639 itself does not create a formulation monopoly.

When does U.S. Patent 9,468,639 expire?

The patent issued on October 18, 2016.[3] Its enforceable term is governed by the patent-term rules applicable to the relevant family, including the earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any applicable regulatory extension.

Public patent records associate the patent family with an expiration period in the mid-2020s. The controlling expiration date should be taken from the current USPTO Patent Center record and the FDA Orange Book listing for the relevant NDA. A patent expiration date stated without checking those records can be wrong because continuation practice, patent-term adjustment, terminal disclaimers, and pediatric exclusivity can change the operative date.

The economic point is clearer than the date dispute: the patent’s remaining exclusionary period is substantially shorter than the normal life of a new chemical entity patent, and generic entry has become the principal competitive issue.

What is the Orange Book status of flibanserin patents?

FDA Orange Book-listed patents for Addyi have included method-of-use patents associated with flibanserin. The relevant listing must be evaluated by NDA, patent number, use code, and expiration date rather than by patent title alone.[4]

An Orange Book listing can support an ANDA Paragraph IV certification if a generic applicant asserts that the listed patent is invalid, unenforceable, or not infringed. A method-of-use listing does not automatically block approval of every generic use. A generic applicant can pursue a section viii statement and omit the patented indication if the FDA-approved label contains non-patented uses. For Addyi, the commercial relevance of a carve-out depends on the scope of the listed use code and whether the remaining label still induces infringement.

The Orange Book is an FDA listing database, not a judicial determination that a patent is valid or infringed.

Which companies have challenged or competed against Addyi?

The principal competitive threat has come from generic-drug manufacturers rather than biosimilar developers.

Generic flibanserin competition

Flibanserin is a chemically synthesized small molecule. Generic applicants use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant legal tools include:

Paragraph IV certifications;
Section viii statements;
The 30-month stay triggered by timely patent litigation;
First-filer or other 180-day exclusivity issues where applicable;
Label carve-outs for patented methods of use.

Teva Pharmaceuticals received FDA approval for a generic flibanserin product, making it a direct competitor to Addyi.[5] Other ANDA applicants may compete through approval, settlement rights, authorized-generic arrangements, or later market entry.

Biosimilar risk

There is no biosimilar pathway applicable to flibanserin. Biosimilars are biological products regulated under the Public Health Service Act. Flibanserin is a small-molecule drug regulated through the ANDA framework. The relevant risk is generic substitution, not biosimilar interchangeability.

What Paragraph IV issues affect Patent 9,468,639?

A Paragraph IV challenge would typically attack one or more of the following:

Issue	Potential defense or challenge
Infringement	The proposed product label omits the patented use, or the label does not direct administration within the claimed scope
Anticipation	Earlier publications disclose flibanserin for decreased, absent, or inhibited sexual desire
Obviousness	Prior art would have made the claimed therapeutic use and dose ranges predictable
Written description	The specification may not adequately support all patient groups, conditions, salts, or dose ranges
Enablement	The full breadth of male and female treatment claims may not be enabled across all doses
Indefiniteness	Terms such as “decreased,” “absent,” “inhibited,” “therapeutically effective,” and “about” may be disputed
Double patenting	Overlap with related flibanserin method-of-use claims may support an obviousness-type double-patenting argument
Enforceability	Prosecution-disclosure, inequitable-conduct, terminal-disclaimer, or maintenance-fee issues may arise

The broadest vulnerability is the gap between a narrow clinical evidence base and the literal breadth of the claims. Claims covering both sexes, multiple diagnostic descriptions, wide dose ranges, and any pharmaceutically acceptable acid-addition salt present a larger validity surface than a claim limited to the FDA-approved population and 100 mg bedtime regimen.

How strong is the patent estate for flibanserin?

The estate is best characterized as moderate for the approved commercial use and weaker outside it.

Estate characteristic	Assessment
Compound protection	Weak or absent for current commercial purposes; the relevant compound protection is old
Approved-use protection	Meaningful because the 100 mg female regimen maps directly to several claims
Formulation protection	Not supplied by Patent 9,468,639
Dose protection	Broad, overlapping ranges create coverage but also validity exposure
Male-use protection	Broad on paper, limited commercial value without an approved indication
Generic defense difficulty	Moderate; the marketed regimen is easy to map to the claims
Patent-term duration	Limited compared with a newly launched NCE
Biosimilar barrier	None
Manufacturing barrier	None apparent from the asserted claims

Patent strength should be evaluated claim by claim. Claim 18 is commercially focused because it recites a dosage unit containing about 100 mg, matching Addyi’s labeled strength. Claims 4, 5, 11, 12, and 17 are broader but may face greater validity challenges. Claims 8 and 14 use overlapping sexual-desire terminology and may raise claim-construction questions because the body of each claim ends with “to treat decreased sexual desire,” even though the preamble refers to absent or inhibited desire.

What patent litigation and settlements affect generic launch?

The key litigation question is whether an ANDA applicant challenged the patent before expiration and obtained a judgment or settlement permitting launch. A settlement can establish an agreed launch date, license terms, authorized-generic rights, supply arrangements, or restrictions on the generic label.

Generic flibanserin approval confirms that the regulatory barrier has been overcome for at least one applicant.[5] Approval does not by itself establish that every patent has expired or that every claim is invalid. It indicates that the applicant satisfied FDA requirements and that any applicable patent certifications, litigation outcomes, settlement terms, or exclusivity barriers permitted approval.

For transaction diligence, the relevant documents are:

The Orange Book patent listing and use code;
The ANDA Paragraph IV notice;
The district-court complaint and docket;
Any settlement or consent judgment;
The FDA approval letter;
The current generic label;
The current Addyi label and distribution terms.

What generic launch scenarios exist for flibanserin?

Full-label generic launch

A generic label that includes the same sexual-desire indication and 100 mg regimen creates the strongest direct risk to Addyi. It would likely compete through pharmacy substitution, payer formulary pressure, and lower net pricing.

Carved-out label

A section viii carve-out could omit a patented method of use. This strategy depends on the use code and whether the remaining labeling still encourages the patented use. A carve-out may reduce infringement exposure but can limit commercial utility.

Authorized generic

An authorized generic can preserve manufacturer control over pricing and channel access while competing against independent ANDA applicants. The economics depend on supply agreements, launch timing, and the scope of any settlement.

Delayed or licensed entry

A settlement may allow entry before nominal patent expiration while preserving the branded company’s position until an agreed date. The settlement can also allocate market entry through a license rather than a court judgment.

How does flibanserin compare with competing sexual-dysfunction drugs?

Product	Active ingredient	Regulatory target	Patent risk profile
Addyi	Flibanserin	Female sexual interest/arousal disorder in premenopausal women	Small-molecule method-of-use and product-label risk
Vyleesi	Bremelanotide	Acquired, generalized hypoactive sexual desire disorder in premenopausal women	Separate compound, formulation, and method-of-use estate
Viagra	Sildenafil	Erectile dysfunction	Mature small-molecule generic market
Cialis	Tadalafil	Erectile dysfunction and related indications	Mature small-molecule generic market
Testosterone products	Testosterone	Hormone deficiency and related uses	Formulation and delivery-system competition

Addyi differs from Viagra and Cialis because its approved use is centrally acting and female-specific, while the leading erectile-dysfunction drugs act through different pharmacology and target a different patient population. Vyleesi is the closest branded therapeutic competitor by indication, but its injectable delivery system and bremelanotide chemistry create a separate patent landscape.

What is the commercial exposure from Patent 9,468,639?

The patent’s commercial exposure is concentrated in Addyi revenue, not in a broad platform business. The key drivers are:

The number of generic entrants;
The timing of generic substitution;
Whether the generic label includes the approved use;
Payer coverage and prior authorization;
Addyi’s cash-pay and telehealth distribution model;
Any authorized-generic strategy;
The durability of the branded product after loss of exclusivity.

Public revenue estimates for Addyi have varied substantially because distribution has shifted among specialty pharmacies, direct-to-consumer channels, telehealth providers, and commercial insurers. A reliable valuation model should use audited company disclosures and current prescription data rather than early launch forecasts.

Key Takeaways

U.S. Patent 9,468,639 is a broad flibanserin method-of-use patent.
Independent claims 1, 8, and 14 cover treating decreased, absent, or inhibited sexual desire.
The claims cover male and female patients, although Addyi’s FDA label is limited to premenopausal women.
The 100 mg Addyi regimen falls within multiple claims, including claim 18.
The patent does not independently protect a formulation, manufacturing process, polymorph, or delivery system.
Flibanserin is a small molecule, so biosimilar risk is irrelevant.
Generic competition proceeds through the ANDA pathway, Paragraph IV certifications, section viii statements, and potential settlements.
Teva’s FDA-approved generic flibanserin confirms material regulatory competition.
The estate is strongest for the labeled 100 mg use and weaker for the broader male-patient, diagnostic, salt, and dose-range coverage.
The operative expiration date must be confirmed in the current USPTO and Orange Book records because patent-term adjustment, terminal disclaimers, and related family rights can affect timing.

FAQs About U.S. Patent 9,468,639 and Flibanserin

Does Patent 9,468,639 cover only women?

No. Claims 3, 10, and 16 expressly cover male patients. The FDA-approved Addyi indication is narrower than the patent claims.

Does a 100 mg flibanserin tablet fall within the patent claims?

Yes. Claim 18 expressly covers a dosage unit containing about 100 mg, and several broader daily-dose claims also encompass the 100 mg regimen.

Is Patent 9,468,639 a patent on Addyi’s tablet formulation?

No. It is a therapeutic method patent. A separate patent would be required to protect a specific tablet composition, excipient system, release profile, or manufacturing process.

Can a generic flibanserin applicant omit the patented indication?

Potentially. An ANDA applicant may use a section viii statement to carve out a patented method of use, but the outcome depends on the Orange Book use code and whether the remaining label induces the patented use.

Does flibanserin have biosimilar competition?

No. Flibanserin is a small-molecule drug. Competition is through generic ANDAs rather than biosimilar applications under the Biologics Price Competition and Innovation Act.

References

U.S. Food and Drug Administration. (2015). FDA approves Addyi to treat sexual dysfunction in premenopausal women. https://www.fda.gov/news-events/press-announcements/fda-approves-addyi-treat-sexual-dysfunction-premenopausal-women
U.S. Food and Drug Administration. (2023). Addyi (flibanserin) prescribing information. Sprout Pharmaceuticals.
United States Patent and Trademark Office. (2016). U.S. Patent No. 9,468,639, Methods of treating sexual dysfunction.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2023). Drugs@FDA: Flibanserin ANDA approval records. https://www.accessdata.fda.gov/scripts/cder/daf/

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01125020	Oct 20, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037109	⤷ Start Trial
Argentina	077480	⤷ Start Trial
Austria	327757	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,468,639

Summary for Patent: 9,468,639